http://www.otplinks.com

This episode examines a serious case involving retatrutide, where an individual experienced an overdose due to improper medication administration. We discuss the critical importance of medication safety and patient safety, especially concerning prescription drugs.The discussion also touches upon a recent report of liver failure following the Foundayo launch, emphasizing the need for vigilant drug safety and thorough error analysis to prevent future incidents.

https://www.otplinks.com

1. 🚨 The 40mg Retatrutide Overdose Case — 0:00:02A 32-year-old self-administered gray market Retatrutide, forgot he'd dosed, injected again — hitting 40mg. The setup for the whole episode.

2. 🏥 What Actually Happened to Him (ER Visit & Why It Matters) — 0:05:02Deep dive into the published medical case: severe diarrhea, dehydration, kidney danger, and the frightening ease with which it happened.

3. ⚠️ Gray Market GLP-1s: The Real Risk Nobody's Talking About — 0:07:20How buying unregulated research peptides means guessing on purity, dose, and contents — and why that's terrifying at scale.

4. 💊 Orforglipron (Fondayo) & the Liver Failure Report — 0:13:00 (approx.)One month after Fonda's launch, a liver failure report emerges. The FDA's concerns, elevated liver enzymes in trials, and why Lilly scaled back from 45mg to 36mg in Phase 3.

5. 🔗 How These Two Stories Connect: Clinical Trials vs. the Real World — 0:16:31The through-line of the episode: drugs behave differently outside controlled settings. Peptide influencers hawking research-grade OrforglprIon pills mid-fast is the canary in the coal mine.

6. 🚪 Compounding Access Is Being Squeezed — State Boards, Lawsuits & the Gray Market Funnel — 0:19:06State medical boards in CA, RI, and KY pressuring doctors. As regulated access tightens, patients don't stop — they just shift to riskier sources.

7. 📱 Introducing the Pivot App: A GLP-1 Tracking Tool for Patients — 0:21:55Interview with Shed's Chief Product Officer Kyler Ockey about the Pivot app — dose logging, daily habit tracking, weekly check-ins, and why patient self-tracking is critical to safe GLP-1 use.

We just got done listening to the quarter one, 2026 Eli Lilly earnings call. There was a lot of information to get into, whether you're interested in retatrutide, eloralintide, or Foundayo, and all of the numbers that were so incredible to hear. This video analyzes Eli Lilly's Q1 2026 earnings call, discussing key products like eloralintide, brenipatide, and retatrutide, providing essential finance news and stock market news for those tracking pharmaceutical companies. The presenter highlights the strong start of Foundayo's U.S. launch and reviews the Lilly Select Pipeline, touching upon the U.S. Incretin Analogs Market and broader healthcare industry trends.

WAYS TO SUPPORT MY WORK ⬇️http://www.otplinks.com💊 OVER THE COUNTER ORAL PEPTIDE SUPPLIMENTS: BPC-157 // Can’t Weight // TB4-FRAG // KPVSign up here and use code “OTP10” to save 10%https://integrativepeptides.com/OTPWHY I TRUST INTEGRATIVE PEPTIDES:🇺🇸 Made in the USA📋 CGMP Compliant (FDA oversight of their products)🧑‍⚕️Trusted and Sold By Doctors and Clinics all over the USA📕 GET MY BOOK! Decoding GLP-1: A Guide for Friends and Family of Those On The Pen By Dave Knapphttps://amzn.to/4gAXrz4